These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 977795)
1. Interpretation of bioavailability data by practitioners. Schumacher GE J Clin Pharmacol; 1976 Oct; 16(10 Pt 2):554-9. PubMed ID: 977795 [No Abstract] [Full Text] [Related]
3. Bioavailability of digoxin in man after oral administration of preparations with different dissolution rate. Nyberg L Acta Pharmacol Toxicol (Copenh); 1977; 40 Suppl 3():1-48. PubMed ID: 301340 [No Abstract] [Full Text] [Related]
4. Recognition of variable bioavailability as an international problem: a review of the earlier studies. Munro-Faure AD; Fowle AS; Fox J; Johnson BF; Lader S Postgrad Med J; 1974 Nov; 50 Suppl 6():14-8. PubMed ID: 4459882 [No Abstract] [Full Text] [Related]
5. The importance of bioavailability to the pharmacist. Canada AT Int J Clin Pharmacol Biopharm; 1975 Jun; 11(4):346-8. PubMed ID: 1158541 [TBL] [Abstract][Full Text] [Related]
6. Use of bioavailability data by practitioners. I: pitfalls in interpreting the data. Schumacher GE Am J Hosp Pharm; 1975 Aug; 32(8):639-42. PubMed ID: 1146833 [TBL] [Abstract][Full Text] [Related]
7. Bioavailability of drugs (second of two parts). Koch-Weser J N Engl J Med; 1974 Sep; 291(10):503-6. PubMed ID: 4604153 [No Abstract] [Full Text] [Related]
8. [Bioavailability of digoxin tablets in Israel]. Levy M; Adler R; Superstein E; Eliakim M Harefuah; 1975 Aug; 89(4):153-4. PubMed ID: 1158280 [No Abstract] [Full Text] [Related]
10. Bioavailability assessment: methods to estimate total area (AUC O to infinity) and total amount excreted (A infinity e) and importance of blood and urine sampling scheme with application to digoxin. Wagner JG; Ayres JW J Pharmacokinet Biopharm; 1977 Oct; 5(5):533-57. PubMed ID: 925886 [No Abstract] [Full Text] [Related]
12. Dissolution and bioavailability of the anhydrate and trihydrate forms of ampicillin. Hill SA; Jones KH; Seager H; Taskis CB J Pharm Pharmacol; 1975 Aug; 27(8):594-8. PubMed ID: 239175 [TBL] [Abstract][Full Text] [Related]
13. Importance of biopharmaceutics and pharmacokinetics in clinical medicine. Cabana BE Arzneimittelforschung; 1976; 26(1A):151-8. PubMed ID: 947194 [TBL] [Abstract][Full Text] [Related]
14. Where are we now and where do we go next in terms of the scientific basis for regulation on bioavailability and bioequivalence? FDA Biopharmaceutics Coordinating Committee. Williams RL; Adams W; Chen ML; Hare D; Hussain A; Lesko L; Patnaik R; Shah V Eur J Drug Metab Pharmacokinet; 2000; 25(1):7-12. PubMed ID: 11032082 [No Abstract] [Full Text] [Related]
16. An overview of the analysis and interpretation of bioavailability studies in man. Wagner JG Arzneimittelforschung; 1976; 26(1A):105-8. PubMed ID: 947190 [TBL] [Abstract][Full Text] [Related]
18. The potential clinical significance of differences in bioavailability. Hosp Formul; 1976 Sep; 11(9):484, 487-8. PubMed ID: 10316482 [No Abstract] [Full Text] [Related]
19. [Bioavailability of drug products and bioequivalence requirements (author's transl)]. Jaminet F J Pharm Belg; 1978; 33(3):141-56. PubMed ID: 682101 [No Abstract] [Full Text] [Related]
20. Which drugs should we be testing for bioavailability. Smith RN Br J Clin Pharmacol; 1975 Feb; 2(1):5-7. PubMed ID: 1234487 [No Abstract] [Full Text] [Related] [Next] [New Search]